DURHAM, N.C. FEBRUARY 04, 2019 - Benjamin “Beno” Freedman, Ph.D., is named STEM CELLS' Young Investigator of 2018 for his groundbreaking work with organoids in studying kidney structure and disease. This award fosters advancements in the fields of stem cells and regenerative medicine by honoring a young researcher who is principal author of an article published in STEM CELLS that is deemed to have the most impact and to push the boundaries of novel and insightful research.
You are here
Press Releases from AlphaMed Press
January 28, 2019
Durham, NC - (January 28, 2019)– A study released today in STEM CELLS Translational Medicine provides a deeper and clearer understanding of how patients suffering vision loss in both eyes due to limbal stem cell deficiency (LSCD) might benefit from a stem cell transplant using donated cells. This is the first randomized, controlled study to investigate the safety and efficacy of this method, in which corneal epithelial stem cells procured from a deceased donor and expanded in the lab were transplanted in the patient’s eye.
January 23, 2019
DURHAM, N.C. JANUARY 23, 2019 - Yong-Beom Park, M.D., Ph.D., is named the STEM CELLS Translational Medicine’s Young Investigator of 2018 for his research in cartilage regeneration in osteoarthritic patients. The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in SCTM that is deemed to have the most impact and to push the boundaries of novel and insightful research.
January 17, 2019
DURHAM, N.C. (JANUARY 17, 2019) - A new study released this week in STEM CELLS Translational Medicine (SCTM) offers hope for anyone who has suffered a serious corneal injury that did not respond well to conventional treatment. It details how an application of freeze-dried mesenchymal stem cell secretome (secreted factors), reconstituted in a gel made up of hyaluronic acid and chondroitin sulfate (HA/CS), not only enhances wound healing, but reduces scarring and other frequent complications, too.
December 17, 2018
DURHAM, N.C. (December 2018) Skeletal (mesenchymal) stem cells (MSCs) are being used in an increasing number of clinical trials for their therapeutic benefits in tissue regeneration and fracture healing. However, their poor homing capacity to the injured site presents a major challenge to realizing their full capabilities. A new study recently published in STEM CELLS shows a possible way to overcome that.
November 19, 2018
Durham, NC (November 19, 2018) – A new study in STEM CELLS Translational Medicine indicates mesenchymal stem cells (MSCs) are a safe and innovative option to heal normal tissue following radiotherapy. Alain Chapel, Ph.D., and Annette Larsen, DVM, Ph.D., of the Institut National de la Santé et de la Recherche Médicale (INSERM) in France led the team that conducted this research.
More than 14 million new cases of cancer are diagnosed globally each year, according to the National Institutes of Health. Of those, half could benefit from radiation therapy. However, radiotherapy can cause substantial damage to a patient’s normal tissue. Mesenchymal stem cells (MSCs) have been used to help alleviate this damage, but their potential to lead to residual tumor cells is worrisome.
November 13, 2018
DURHAM, N.C. NOVEMBER (2018) - A new study released today in STEM CELLS Translational Medicine demonstrates how a biodegradable hydrogel sponge seeded with olfactory stem cells (OSCs) greatly accelerated recovery from facial palsy in mice. The technique, developed by a team of researchers at Nagoya City University, Japan, shows potential for treating humans suffering from this condition — a frequent result of temporal bone fractures — as well as from other similar trauma or diseases such as Bell’s palsy or Ramsay Hunt syndrome, a painful byproduct of shingles.
November 5, 2018
Durham, NC (November 5, 2018) – A study recently published in STEM CELLS Translational Medicine (SCTM) describes a new cell therapy that shows promise in treating cirrhosis of the liver. The treatment, combination of mesenchymal stem cells and induced bone marrow-derived macrophages, reduced fibrosis and promoted regeneration of cirrhosis-damaged liver in tests on mice.
October 31, 2018
Durham, NC (October 31, 2018)– A study released today in STEM CELLS moves scientists a step closer to finding how to help the body regenerate joint cartilage ravaged by disease. Their work reveals a new method to quickly and efficiently produce virtually unlimited numbers of chondrocytes, the cells that form cartilage, from human skin cells converted to induced pluripotent stem cells (iPSCs). For the 54 million Americans suffering from arthritis – the nation’s Number One disability – this could be great news.
October 8, 2018
DURHAM, N.C. (PRWEB) OCTOBER 08, 2018
A new study published in STEM CELLS Translational Medicine shows that the energy metabolism of human mesenchymal stem cells (hMSCs) can be targeted to increase their ability to enhance tissue regeneration. The study offers a strategy that has immediate translational potential for improving hMSCs’ therapeutic success.
hMSCs have gained significant interest as an “off-the-shelf” product for cell therapy in various types of diseases. Recent findings suggest that instead of replacing damaged cells through differentiation, as initially thought, hMSCs promote tissue regeneration by coordinating multiple components of the host immune system via the release of immunomodulatory factors. Therefore, understanding the mechanism underpinning hMSC immune polarization and secretory function is critical to enhancing their therapeutic outcome.
